AI Could Flag Problematic Healthcare Contract Terms
Employers buying health coverage could use AI agents to review contracts for problematic terms before signing.
Updated on Nov. 1, 2026 in Healthcare
Live Poll
Do you think healthcare costs will get lower in the next few years?
Mark Cuban said on a recent a16z podcast episode that AI agents could review healthcare contracts before employers sign them, flagging problematic terms and helping employers decide what to negotiate. He cited a 1,335-page contract between the city of Dallas and a pharmacy benefit manager as an example of the complexity involved.
Why it matters
Healthcare contracts are complex and hard to negotiate, and Cuban argued that AI-assisted review could shift leverage toward employers purchasing coverage. The argument rests on the view that the healthcare system is fundamentally inefficient, so tools that expose contract terms could alter how buyers approach vendor agreements.
The Dallas-PBM contract runs 1,335 pages, and Cuban cited 67% of employers representing 160M+ Americans as potential users of AI contract review. UnitedHealth Group has more than 3,000 subsidiaries and moves roughly $150 billion through intercompany transfers each year.
The players
Mark Cuban
Entrepreneur and investor known for his ownership of the Dallas Mavericks and his involvement with the pharmacy company Cost Plus Drugs.
UnitedHealth Group
Large diversified healthcare company with more than 3,000 subsidiaries and a major presence in insurance and pharmacy benefit services.
Cost Plus Drugs
Pharmacy company that sells generic and branded medicines at cost-plus pricing and uses AI and robotics in its manufacturing.
The details
Under Cuban's proposal, an employer would ask an AI agent to examine a healthcare contract and identify problematic terms. The tool would highlight those terms, explain what they mean in plain language, and help the employer determine what to negotiate before signing. Cuban also said AI and robotics already used in manufacturing by Cost Plus Drugs, including modular production pods for smaller facilities, could eventually push the cost of personalized drug design toward zero.
Timeline
Cuban's remarks on AI and healthcare contracts were published on November 1, 2026.
Market Landscape
Cost Plus Drugs' model of selling medicines at cost-plus pricing is the operating precedent Cuban pointed to when describing AI-enabled production. The argument extends from manufacturing into contract administration, where pharmacy benefit managers and large insurers have historically controlled the terms.
Employers that buy health coverage or pharmacy benefit services should consider whether AI-assisted contract review could sharpen their negotiating position before signing renewals. Procurement and finance teams should treat AI contract tools as an emerging option rather than an established practice, since the cost claims remain untested.
The takeaway
Operators who buy health benefits should ask whether their contracts can be reviewed for problematic terms before signing and track whether vendors respond to that scrutiny. Calendar contract renewal dates so any AI-assisted review can happen before terms are locked in, and consult qualified counsel on contract changes.
Further reading
For broader context on how these pricing and contract pressures are reshaping the sector, see Healthcare coverage on We are Main Street.
Source note: This article includes information reported by Benzinga.
Live Poll
Do you think healthcare costs will get lower in the next few years?
